Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans. by Wigger, L. et al.
ArticlePlasma Dihydroceramides Are Diabetes
Susceptibility Biomarker Candidates in Mice and
HumansGraphical AbstractHighlightsd Shotgun lipidomics was performed on plasma samples from
mice and humans
d In mice, several sphingolipids correlate with diabetes-like
traits
d In human cohorts progressing to diabetes, dihydroceramide
levels are elevated
d A significant increase was found in two cohorts, up to 9 years
before disease onsetWigger et al., 2017, Cell Reports 18, 2269–2279
February 28, 2017 ª 2017 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2017.02.019Authors
Leonore Wigger,
Ce´line Cruciani-Guglielmacci,
Anthony Nicolas, ..., Christophe Magnan,
Mark Ibberson, Bernard Thorens
Correspondence
mark.ibberson@sib.swiss (M.I.),
bernard.thorens@unil.ch (B.T.)
In Brief
Wigger et al. find that several
sphingolipids in mouse plasma correlate
with glucose tolerance and insulin
secretion. Quantitative analysis of these
and closely related lipids in human
plasma from two cohorts reveal that
dihydroceramides are significantly
elevated in individuals progressing to
diabetes, up to 9 years before disease
onset.
Cell Reports
ArticlePlasma Dihydroceramides Are
Diabetes Susceptibility Biomarker
Candidates in Mice and Humans
Leonore Wigger,1,2 Ce´line Cruciani-Guglielmacci,3 Anthony Nicolas,4,5,6,7 Jessica Denom,3 Neı¨ke´ Fernandez,3
Fre´de´ric Fumeron,4,5,6,7 Pedro Marques-Vidal,8 Alain Ktorza,9 Werner Kramer,10 Anke Schulte,11 Herve´ Le Stunff,3,12
Robin Liechti,1 Ioannis Xenarios,1 Peter Vollenweider,8 Ge´rard Waeber,8 Ingo Uphues,13 Ronan Roussel,4,5,6,7
Christophe Magnan,3 Mark Ibberson,1,* and Bernard Thorens2,14,*
1Vital-IT Group, SIB Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland
2Center for Integrative Genomics, University of Lausanne, 1015 Lausanne, Switzerland
3Unite´ de Biologie Fonctionnelle et Adaptative (BFA), CNRS UMR 8251, Universite´ Paris Diderot, Sorbonne Paris Cite´, 75205 Paris,
France
4INSERM, Sorbonne Paris Cite´, Centre de Recherce des Cordeliers (CRC), UMR_S 1138, 75006 Paris, France
5UPMC, Sorbonne Universite´s, Centre de Recherce des Cordeliers (CRC), UMR_S 1138, 75006 Paris, France
6Universite´ Paris Descartes, Sorbonne Paris Cite´, Centre de Recherche des Cordeliers (CRC), UMR_S 1138, 75006 Paris, France
7Universite´ Paris Diderot, Sorbonne Paris Cite´, Centre de Recherches des Cordeliers (CRC), UMR_S 1138, 75006 Paris, France
8Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland
9Recherche de De´couverte, PIT Me´tabolisme, Institut de Recherche Servier (IdRS), 92150 Suresnes, France
10Biomedical and Scientific Consulting, 55130 Mainz, Germany
11Diabetes Research, Islet Biology Cluster, Sanofi-Aventis Deutschland GmbH, Industriepark Ho¨chst, 65926 Frankfurt am Main,
Germany
12Institut de biologie inte´grative de la cellule (I2BC), CNRS UMR 9198, Universite´ Paris-Sud, Universite´ Paris-Saclay, 91190 Gif-sur-Yvette,
France
13Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach (Riss), Germany
14Lead Contact
*Correspondence: mark.ibberson@sib.swiss (M.I.), bernard.thorens@unil.ch (B.T.)
http://dx.doi.org/10.1016/j.celrep.2017.02.019SUMMARY
Plasma metabolite concentrations reflect the activ-
ity of tissue metabolic pathways and their quan-
titative determination may be informative about
pathogenic conditions. We searched for plasma lipid
species whose concentrations correlate with various
parameters of glucose homeostasis and susceptibil-
ity to type 2 diabetes (T2D). Shotgun lipidomic anal-
ysis of the plasma of mice from different genetic
backgrounds, which develop a pre-diabetic state
at different rates when metabolically stressed, led
to the identification of a group of sphingolipids
correlated with glucose tolerance and insulin secre-
tion. Quantitative analysis of these and closely
related lipids in the plasma of individuals from two
population-based prospective cohorts revealed
that specific long-chain fatty-acid-containing dihy-
droceramides were significantly elevated in the
plasma of individuals who will progress to diabetes
up to 9 years before disease onset. These lipids
may serve as early biomarkers of, and help
identify, metabolic deregulation in the pathogenesis
of T2D.Cell Rep
This is an open access article undINTRODUCTION
Type 2 diabetes mellitus (T2D) is diagnosed based on elevated
fasting glycemia and abnormal glucose tolerance tests. These
deregulations are caused by genetic and lifestyle factors, which
lead to the failure of beta cells to secrete enough insulin to
compensate for the insulin resistance of liver, fat, and muscles.
The specific pathogenic mechanisms that lead to the imbalance
between insulin secretion and insulin action are, however, poorly
understood. Nevertheless, it is known that initial defects in
specific metabolic, signaling, or differentiation pathways in
pancreatic beta cells or insulin target tissues may all induce
whole body functional deregulations that ultimately cause T2D.
This is exemplified by the various forms of maturity onset dia-
betes of the young (MODY) (Bonnefond and Froguel, 2015),
which are monogenic forms of diabetes affecting mostly pancre-
atic beta-cell function, or by numerous studies of mice with cell-
specific inactivation of genes involved in insulin signaling or
insulin secretion, which all develop T2D (Baudry et al., 2002).
Thus, T2D may have multiple initial causes and identifying
them before the onset of hyperglycemia may help develop pre-
ventative strategies or therapeutic approaches based on spe-
cific pathogenic mechanisms.
Identification of circulating biomarkers that could predict the
susceptibility to T2D and be used to monitor the progression of
the disease is important in developing better treatments and inorts 18, 2269–2279, February 28, 2017 ª 2017 The Author(s). 2269
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
designing innovative clinical trials. Plasma metabolomic studies
may identify such biomarkers. Indeed, it has been hypothesized
many years ago (Pauling et al., 1971) that quantitative determina-
tion of plasma metabolite concentrations could give precise in-
formation about the activity of specific metabolic pathways,
the functional state of the organs in which they operate, and their
deregulations in pathogenic conditions. Many studies have
searched for plasma metabolite biomarkers for T2D susceptibil-
ity (Ferrannini et al., 2013; Stanca´kova´ et al., 2012; W€urtz et al.,
2012; Zhao et al., 2010), but predictive biomarkers for T2D are
not yet available, in particular, because the combination of
several biomarkersmay be needed to obtain sufficient prediction
power (Cobb et al., 2015). Finding such biomarkers is critical to
identify the original metabolic deregulations that cause T2D.
These biomarkers can then be used to classify diabetes accord-
ing to the causal pathogenic mechanisms and develop personal-
ized treatment of the disease.
It would be advantageous to find biomarkers that are simi-
larly predictive of disease susceptibility in mouse and humans.
Indeed, animal studies are critical to (1) experimentally deter-
mine whether the circulating biomarker correlates with or in-
duces beta-cell dysfunction or insulin resistance in liver, fat,
or muscle and (2) identify the tissue that produces the
biomarker as this may become a therapeutic target. On the
other hand, population-based prospective cohorts are required
to validate the prognostic value of the biomarker, which may be
coupled, for instance, to already gathered genetic data to
potentially provide composite biomarkers of higher predictive
power.
It is well established that mice fed a high-fat (HF) diet develop
a form of pre-diabetes characterized by obesity, mild fasting hy-
perglycemia, hyperinsulinemia, insulin resistance, and glucose
intolerance (Burcelin et al., 2002; Surwit et al., 1988). However,
the metabolic deregulations induced by high-fat diet feeding are
largely influenced by the genetic background (Andrikopoulos
et al., 2005; Rossmeisl et al., 2003; Surwit et al., 1995). Thus,
studying adaptation of mice from diverse genetic backgrounds
to metabolic stress offers a powerful way to identify the
changes in plasma metabolites that are most relevant to assess
the risk of developing T2D. The availability of population-based
prospective cohorts such as data from an epidemiologic study
on the insulin resistance syndrome (DESIR) cohort (Balkau
et al., 2008) and Cohorte Lausannois (CoLaus) (Firmann et al.,
2008), which comprise hundreds of individuals who have pro-
gressed from a healthy state to T2D, provide a unique resource
for the validation of the biomarkers identified in pre-clinical
models.
In the present study, we report the identification of a group of
sphingolipids associated with impaired glucose tolerance and
altered insulin secretion in mice exposed to metabolic stress.
Targeted analysis of these sphingolipids in over 250 individuals
from two different prospective cohorts who developed T2D re-
vealed that the plasma concentrations of dihydroceramide and
ceramide species are significantly elevated as compared to con-
trol individuals up to 9 years before development of T2D. These
sphingolipids are therefore biomarkers for T2D susceptibility and
may help identify primary metabolic deregulation in the patho-
genesis of T2D.2270 Cell Reports 18, 2269–2279, February 28, 2017RESULTS
Plasma Levels of Certain Ceramides and Ceramide
Derivatives Correlate to Glucose Tolerance and Insulin
Secretion in Metabolically Challenged Mice
Mice from six genetically different mouse strains (C57BL/6J,
DBA/2J, 129S2/SvPas, AKR/J, A/J, and BALB/cJ) were fed a
high-fat, high-sucrose (HFHS) or regular chow (RC) diet for 2,
10, 30, or 90 days, after which time several phenotypic measure-
ments were performed, including glycemia, insulinemia, glucose
tolerance, and in vitro glucose-stimulated insulin secretion
(detailed study to be reported separately). At each time point
and for each mouse strain and diet, plasma samples were taken
from six different mice and analyzed using a combined shotgun
and targeted lipidomics strategy. In this strategy, 135 molecular
lipids of 19 different lipid classeswere quantified including sphin-
golipids [ceramides Cer(d18:1), dihydroceramides Cer(d18:0),
ceramide derivatives, and sphingosine] and triacylglycerides
(TAGs) (see Experimental Procedures). The plasma lipids
showed distinct profiles across samples, where both genetic
background and diet strongly influenced plasma lipid concentra-
tions. This can be seen by distinct patterns of high and low lipid
concentrations across the mouse strains on different diets and
different time points in the study (Figure S1). We next correlated
the lipids to each of the phenotypic traits in order to identify those
lipids that were potentially associated with mouse phenotypes
related to pancreatic dysfunction and diabetes. Figure 1 shows
a network representation of the strongest lipid trait correlations
(absolute Spearman correlation jrs jR0:4) with lipids and pheno-
typic traits as nodes and correlations as edges. Lipids were
selected for further investigation (marked with red borders in Fig-
ure 1) if they were (1) strongly correlated to glucose tolerance or
insulin secretion or both, which we regarded as the primary traits
of interest in mice, and (2) in addition to these to one or several of
HOMA-B, HOMA-IR, and fasting insulin. Correlation data that
were used to generate the network in Figure 1 are included in
Table S1. Three ceramides, one dihydroceramide, and two lac-
tosylceramides satisfied these criteria due to their correlations
with several traits including glucose intolerance and insulin
secretion and were selected for further investigation. Correlation
data for these selected lipids with the different phenotypic traits
are included as a separate sheet in Table S1. Scatterplots of
these lipids showing correlations with six mouse traits are shown
in Figure S2. Most of them are positively correlated to glucose
intolerance (area under the curve [AUC] of glycemia) and nega-
tively correlated to insulin sensitivity (AUC of insulinemia) as
well as positively correlated to fasting insulin, insulin secretion,
and HOMA-B, suggesting that they might be early markers of
the pre-diabetic phenotype induced by high-fat diet in mice.
The plasma levels of many of these sphingolipids were also
significantly increased by HFHS diet but to differing degrees in
the six mouse strains (Figure S3; Table S2). There are also
marked differences between certain strains. For example,
Cer(d18:1/22:0) (SwissLipids ID: SLM:000392149) plasma con-
centration increased over time in both RC and HFHS-fed mice
in DBA/2J, but started high and decreased over time in BALB/
cJ mice. BALB/cJ mice are interesting since they showed the
strongest early diabetic phenotype compared to the other
Figure 1. Ceramides Are Correlated to Glucose Intolerance and Insulin Sensitivity in Metabolically Challenged Mouse Strains
Lipid-trait network showing plasma lipid correlations with five measured phenotypic traits. Correlations are represented as edges between lipid nodes and trait
nodes. Only correlations with absolute valueR0.4 are shown. The graph was produced using the ForceAtlas2 layout inGephi 0.9.1with scaling = 10, gravity = 1,
and edge weight influence =1, and overlapping labels were adjusted using Label Adjust. Each trait node is depicted as a different color, and edges are colored
according to the correlated trait. Edge width is proportional to correlation strength from minimum 0.4 to maximum 0.65. Solid edge lines indicate positive
correlations; dashed lines indicate negative correlations. Node label size is proportional to degree (total number of connections). Ceramide lipids that were
chosen for further investigation based on their correlations to several mouse traits are boxed in red. (See Table S1 for the correlation data fromwhich the network
was constructed.)strains (C.C.-G., J.D., N.F., R.L., L.W., I.U., I.X., H.L.S., B.T.,
C.M., M.I., L. Bellini, M. Oshima, P. Normandie-Levi, X.P.
Berney, N. Kassis, C. Rouch, J. Dairou, T. Gorman, D. Smith,
A. Marley, D. Kuznetsov, F. Burdet, A.-L. Lefe`vre, I. Wehrle,
T. Hildebrandt, W. Rust, C. Bernard, A. Ktorza, G.A. Rutter,
and R. Scharfmann, unpublished data). It is therefore intriguing
that plasma levels of all six of the sphingolipid species on RC
diet were higher in BALB/cJ compared to the other strains (Fig-
ure S3), suggesting that plasma levels of these lipids might indi-
cate predisposition to high-fat-induced diabetes in mice.
A Class of Ceramides Is Elevated in Human Plasma 9
Years before Disease Diagnosis
The results in mouse prompted us to investigate whether the
same or similar sphingolipid species were associated with pre-
diabetes in humans. We therefore performed targeted ceramide
lipidomics on plasma samples from a longitudinal human cohort
(DESIR). Samples from this cohort were divided into a control
group and three groups of cases, corresponding to different
time durations from inclusion in the study to disease diagnosis:
group 1 contained individuals who were diagnosed with T2D at
3 years; group 2 were diagnosed at 6 years, and group 3 at
9 years. In each group, plasma samples were obtained every
3 years: for group 1, there were two sets of samples (baseline
and follow-up at 3 years, n = 81 and n = 82), for group 2 three
sets (baseline, 3 and 6 years (T2D diagnosis), n = 48, n = 49,n = 48) and for group 3 four sets (baseline, 3, 6, and 9 years
(T2D diagnosis), n = 62, n = 62, n = 61, n = 61). For the control
group, there were also four sets (baseline, 3, 6, and 9 years,
n = 105, n = 102, n = 104, n = 97). Within each group, the number
of samples n available at each time point differed slightly due to
missing samples and samples excluded because of quality is-
sues. The definition of T2D diagnosis was that an individual either
had a fasting glucose level above 7 mmol/L or was under antidi-
abetic drug treatment at the time of sample collection. We per-
formed statistical comparisons correcting for age and sex,
comparing cases and controls at baseline, 3, 6, and 9 years for
the three groups (see Experimental Procedures). We found that
several of the ceramide species that were correlated to glucose
intolerance in mouse, namely, Cer(d18:1/18:0) (SwissLipids
ID: SLM:000392135), Cer(d18:1/20:0) (SLM:000392142), and
Cer(d18:1/22:0) (SLM:000392149), were significantly elevated
in the plasma of patients 3 years before T2D diagnosis (Figure 2),
but this was only observed in a single group of patients (group 1).
Remarkably, we found that the class of dihydroceramides,
Cer(d18:0), which are precursors of the ceramides and differ
from them by a single double bond (Aimo et al., 2015), were
significantly and reproducibly elevated in the plasma of all
groups of patients at all time points of the study compared to
controls (Figure 2). Dihydroceramide species Cer(d18:0) were
elevated in plasma samples of patients up to 9 years prior to
T2D diagnosis. Figure 3B shows details of the fold change andCell Reports 18, 2269–2279, February 28, 2017 2271
Figure 2. Dihydroceramides Are Elevated in
Plasma up to 9 Years before Incident Disease
Heatmap of t statistics calculated between diabetic
subjects and the control samples corrected for age
and sex. The mean lipid concentration from each
subject group at each time point was compared to
the mean lipid concentration from the control group
taken during the same sample collection period.
White, no difference between diabetic and control
group; red, higher value in diabetic group; blue,
lower value in diabetic group. Asterisks indicate
significance of differences between cases and
controls (*adjusted p < 0.05, **adjusted p < 0.01,
***adjusted p < 0.001, p values adjusted for multiple
correction across 37 lipids by the Benjamini-Hoch-
berg method).significance for ceramide changes 9 to 3 years before diag-
nosis compared to controls for group 3, highlighting the
Cer(d18:0) class lipids. The fold change difference in mean dihy-
droceramide Cer(d18:0) concentrations observed between
cases and controls remains stable over time (Figure 3A). Addi-
tional correction for BMI or low-density lipoprotein (LDL) dimin-
ished the statistical significance of case-control differences,
but the overall pattern remained the same (Figure S4). Interest-
ingly, one of the dihydroceramides showing the most signifi-
cant differences between cases and controls, Cer(d18:0/22:0)
(SwissLipids ID: SLM:000392085), was also significantly posi-
tively correlated to glucose intolerance in mouse (Figures 1
and S2). These results suggest that dihydroceramide plasma
levels could be stably associated with T2D predisposition.
Dihydroceramides Are Elevated in Plasma 5 Years
before Disease Onset in an Independent Cohort
We sought to validate our findings from the DESIR cohort in an
independent cohort. We performed targeted lipidomics analysis
on plasma samples from the CoLaus cohort at baseline and
5 years (T2D diagnosis). The number of samples n in each group
was 150, less a small number of samples (up to three per group
and time point) that were either entirely missing or excluded after
the lipidomics analysis (for sample numbers, see Table S6). The
results (Figure 2) showed elevated plasma concentrations of the
same dihydroceramide Cer(d18:0) species that were signifi-
cantly elevated in the DESIR cohort at baseline and diagnosis,
thus confirming our previous results. Similar to the results ob-
tained for the DESIR cohort, Cer(d18:0) levels are elevated to
similar levels at both baseline and diagnosis, indicating that
this lipid class could be associated with T2D predisposition2272 Cell Reports 18, 2269–2279, February 28, 2017(Figure 4A). Interestingly, many of the
Cer(d18:1) lipids (ceramides) that were
significantly different between cases and
controls in group 1 of the DESIR cohort
(baseline 3 years before T2D diagnosis)
and in the mouse study (Figures 1 and
S2) were also significantly elevated in
CoLaus 5 years prior to diagnosis (Fig-
ure 2). Additional correction for BMI, LDL,
insulin or glycemia had little effect on thesignificance of observed increases of ceramide Cer(d18:1) or
dihydroceramide Cer(d18:0) levels at baseline in CoLaus,
although insulin and glycemia had a larger effect on groups 2
and 3 of the DESIR cohort (Figures S4 and S5).
High Plasma Levels of Dihydroceramides May Be
Associated with an Increased Risk of Future Diabetes
Logistic regression models were performed on both the DESIR
and the CoLaus data in order to compute adjusted odds ratios
for Cer(d18:0) and Cer(d18:1) species. Results from the DESIR
cohort, from all three groups at all time points before diabetes
incidence, are shown in Table S7. The basic model included
age and sex as covariates besides the lipid concentration. Addi-
tional models included one further covariate (BMI, LDL, fasting
glucose, insulin, HOMA2-%B, HOMA2-%S, and waist circum-
ference). The odds ratios provided are ‘‘inter-quartile range
odds ratios’’; that is, they are calculated per increase of the lipid
concentration by an amount equal to the difference between the
top and bottom quartile. There are marked differences in the re-
sults from the three groups of study participants. Results from
group 1 (3 years before diabetes) show odds ratios greater
than 2 for the total dihydroceramides concentration and for the
three Cer(d18:1) ceramides, regardless of the other covariates
added to the model. In groups 2 and 3 (6 and 9 years before dia-
betes, respectively), dihydroceramides have lower but still signif-
icant odds ratios than for group 1 from the basic regression
model with age and sex, but, if glucose or insulin is added to
the model, the odds of belonging to the diabetic group are not
significantly increased in patients with higher lipid concentration
(confidence intervals of odds ratios tend to span 1 or come close
to 1). Similarly, except for Cer(d18:1/18:0) in group 2 at year 0,
AB
Figure 3. Mean Lipid Concentration of Dihy-
droceramides Are Significantly Elevated at
All Time Points in the DESIR Study
(A) Mean plasma concentrations of dihydrocer-
amides plotted over time. The left two plots
show individual lipid species that represent well
the behavior of the class Cer(d18:0/22:0) and
Cer(d18:0/24:0). The rightmost plot represents the
class total for Cer(d18:0). The group means are
consistently higher in diabetes cases as compared
to control samples. x axis: time point of collection.
y axis: mean lipid concentration in each of the
groups. Error bars: SEM of the lipid concentration.
Asterisks at each time point represent significance
of the statistical test comparing cases to controls
(age- and sex-corrected linear model): *adjusted
p < 0.05, **adjusted p < 0.01, ***adjusted p < 0.001
(p values adjusted for multiple correction across 37
lipids by the Benjamini-Hochberg method).
(B) Volcano plots of statistical tests comparing 37
lipid species in each group of diabetic subjects
versus the control samples from the same
sample collection period (linear model, containing
factors for sex and age). A single lipid class is
robustly increased in all diabetic groups and at
all time points, before and after onset of dia-
betes: Cer(d18:0), dihydroceramides. Cer(d18:0/
22:0) (highlighted in red), which was identified in the
mouse study as strongly correlated to the AUC of
glycemia, was elevated at all time points shown.
x axis: log2 fold change between cases and con-
trols. y axis: log10 of the p value. Circles with blue
outlines: the five lipid species from class Cer(d18:0).
Solid blue circle: the class total from class
Cer(d18:0). The plots shown are from DESIR
group 3, at 9 (left), 6 (center), and 3 (right) years
before subjects were identified as diabetic.none of the three ceramides from Cer(d18:1) show odds ratios
significantly different from 1 in groups 2 and 3.
Results from CoLaus are shown in Table 1. The same logistic
regression models were applied as for the DESIR cohort, except
that bioimpedance was also included (this was not available for
the DESIR cohort). For an individual whose plasma lipid concen-
tration was at the top quartile at baseline, the sex- and age-
adjusted odds of belonging to the group that became diabetic
were around two to 2.5 times higher than theywere for an individ-
ual at the bottom quartile, depending on lipid species [example:
Cer(d18:0/24:0), adjusted odds ratio 2.37, 95%CI, 1.69–3.33]. In
all tests, the lower limit of the 95% confidence interval remains
above 1. This suggests that a high plasma level of any of these
lipids is associated with an increased risk of future diabetes
compared to low plasma level. Inclusion of BMI, LDL, or fasting
glucose as covariates in the model results in smaller odds ratios
than the basic model, but the lower bound of the confidence in-
tervals remains above 1, indicating that the association remains
significant.
Decision curve analysis (Rousson and Zumbrunn, 2011; Vick-
ers and Elkin, 2006) was performed as described in Experimental
Procedures. Briefly, this analysis quantifies the predictive value
of a potential biomarker using a net benefit measure that canbe plotted as a curve for different probability cutoffs. Decision
curve results for CoLaus suggests that the Cer(d18:0) lipid class
is a better predictor (higher net benefit) for T2D outcome than
LDL, HOMA2-%B, and HOMA2-%S (Figure 5). Fasting glucose
by itself is the strongest predictor among the variables that
were tested. The combined model of the lipid class and fasting
glucose has about the same net benefit as themodel with fasting
glucose by itself. Adding the lipid does not appear to improve the
prediction above glucose alone (Figure 5). Similar results were
obtained from analysis of the DESIR cohort (data not shown).
On the other hand, the results also suggest that a combined
model of the lipid class and BMI is a better predictor than BMI
by itself. The same is true for waist circumference, bio-
impedance, and insulin (Figure 5), suggesting that Cer(d18:0)
lipids may constitute a plasma biomarker that could be used in
combination with other measures to help predict T2D.
DISCUSSION
In the present study, we first investigated the plasma lipidome of
mice from different genetic backgrounds exposed to ametabolic
stress for different periods of time. The rationale for these exper-
iments is that because of their diverse genetic architectures, theCell Reports 18, 2269–2279, February 28, 2017 2273
AB
Figure 4. Dihydroceramides Are Elevated in
Plasma 5 Years before Incident Disease in
an Independent Cohort
(A) Group means of dihydroceramides (Cer(d18:0)
are elevated in diabetic cases compared to con-
trols, both at baseline (5 years before) and at dia-
betes onset. Asterisks at each time point represent
significance of the statistical test comparing cases
to controls (age- and sex-corrected linear model):
*adjusted p < 0.05, **adjusted p < 0.01, ***adjusted
p < 0.001 (p values adjusted for multiple correction
across 37 lipids by the Benjamini-Hochberg
method).
(B) Volcano plots of statistical tests comparing 37
lipid species in each group of diabetic subjects
versus the control samples from the same sample
collection period (linear model, containing factors
for sex and age). The same Cer(d18:0) class of di-
hydroceramides is significantly increased in plasma
at 5 years before and at disease diagnosis. Lipids
highlighted in red were identified in the mouse study
as strongly correlated to AUC of glycemia and were
elevated at 5 years before [Cer(d18:1/22:0)] or both
at 5 years before and at diagnosis [Cer(d18:1/18:0),
Cer(d18:0/22:0)]. x axis: log2 fold change between
cases and controls. y axis: log10 of the p value.
Circles with blue outlines: the five lipid species from
class Cer(d18:0). Solid blue circle: the class total
from class Cer(d18:0).selected mouse strains display different phenotypic adaptation
to HFHS feeding. Thus, if a group of lipids correlates strongly
with a given phenotype across strains, it is likely to represent a
general biomarker for susceptibility to develop T2D. The overall
goal of the mouse experiment was to select the most likely
biomarker candidates to follow up in human cohorts. Following
this approach, we identified a group of sphingolipids as being
correlated with insulin secretion and glucose intolerance.
Several of those were also found to be strongly associated
with the risk to develop T2D in both the DESIR and CoLaus
cohorts.
In mice, three ceramides [Cer(d18:1/18:0, 20:0 and 22:0)], two
lactosylceramides (LacCer18:1/22:0 and 24:1), and one dihydro-
ceramide [Cer(d18:0/22:0)] were found at a central interaction
point in a lipid-phenotype correlation network between glucose
intolerance, insulin secretion, fasting insulin, and HOMA-B. In
both human cohorts, the susceptibility to develop T2Dwas asso-
ciated with increased plasma levels of several ceramide and
dihydroceramide species, of which the ceramides Cer(d18:1/
18:0), Cer(d18:1/20:0), Cer(d18:1/22:0), and the dihydrocera-
mide Cer(d18:0/22:0) were also found in pre-diabetes in mice.2274 Cell Reports 18, 2269–2279, February 28, 2017The fact that the same group of sphingoli-
pids was associated with susceptibility
to T2D in two separate cohorts as well
as in mice strongly suggests that they
may represent reliable biomarkers. This is
further supported by the fact that a signifi-
cant association of these lipids, but, in
particular, the dihydroceramides in DESIR
group 1 and in CoLaus samples, withT2D risk is conserved even after correction for LDL, BMI, or gly-
cemic levels as covariates. These observations also suggest that
in humans dihydroceramides may play a particular role in T2D
progression.
Dihydroceramides are produced in the third step of the
de novo ceramide biosynthetic pathway initiated by serine pal-
mitoyl transferase. They are converted into ceramides by cer-
amide desaturase, of which two isoforms exist, the ubiquitously
expressed Des1, and Des2 which is expressed mostly in the gut
and skin (Bikman and Summers, 2011). Despite being once
considered inert sphingolipid precursors, dihydroceramides
have recently been proposed as biomarkers of metabolic
dysfunction (Siddique et al., 2015). Circulating levels of dihydro-
ceramides were shown to be elevated in T2D in young adults
(Lopez et al., 2013) and have been associated with waist circum-
ference (Mamtani et al., 2014) and severity of insulin resistance
(Brozinick et al., 2013). At cellular levels, increased concentra-
tions of dihydroceramides can regulate autophagy, reactive
oxygen species production, cell proliferation, and apoptosis
(Rodriguez-Cuenca et al., 2015; Siddique et al., 2015). This has
been studied in detail in 3T3-L1 adipocytes where silencing of
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.Des1 expression or its pharmacological inhibition decreases
adipocytes proliferation, differentiation, and function (Barbarroja
et al., 2015). Addition of fenretinide (N-(4-hydroxyphe- nyl)retina-
mide, FEN), an inhibitor of Des1 (Bikman et al., 2012), to human
cells leads to accumulation of dihydroceramides (Zheng et al.,
2006). Increased dihydroceramide levels in HFHS-fed mice
treated with FEN are associated with improvements in glucose
homeostasis (Mody and Mcilroy, 2014). However, FEN is also
an antagonist of retinoic acid receptor (RAR), and the effect of
this drug on metabolic diseases is complex and not restricted
to the increase in dihydroceramides (Mcilroy et al., 2013, 2016).
Thus, an increase in plasma levels of dihydroceramides may
have multiple effects on specific cellular functions, which may,
combinedwith the already well described role of ceramides in in-
duction of insulin resistance (Bikman and Summers, 2011;
Chaurasia and Summers, 2015), contribute to induce T2D. The
potential impact of elevated dihydroceramides on insulin secre-
tion and insulin action will need to be tested specifically; avail-
ability of relevant preclinical models will be important for these
purposes. It will also be important to determine which tissue
produces these sphingolipids. This could be investigated by
assessing the tissue expression of the six different ceramide
synthase (Cers) isoforms with a focus on Cers2, Cers3, and
Cers4, which preferentially catalyze the formation of very long-
chain fatty-acid-containing ceramides (Chaurasia and Sum-
mers, 2015). On the other hand, reduced expression of Des1
and Des2 may also explain the increased accumulation of dihy-
droceramides. Of note, the Des1 gene was found to be associ-
ated with increased fat mass accumulation in a genetic screen
in HFHS-fed recombinant inbred mice (Parks et al., 2013).
The fact that the identified ceramides and dihydroceramides
contain long-chain fatty acids of diverse desaturation levels
also suggests that beyond changes in ceramide biosynthetic
pathways, changes in fatty-acid-modifying pathways may
contribute to the chemical diversity of the ceramides. We know
from previous studies (Ding et al., 2013) that the NC diet does
not contain fatty acids with chain length R20 carbons. Thus,
the presence of sphingolipids with R20 carbon fatty acids of
diverse desaturation levels most likely reflects contribution of
elongases and desaturases acting on ingested or newly synthe-
sized fatty acids (Guillou et al., 2010).
Collectively, our data show that combining lipidomic analysis
in preclinical models and in human prospective cohorts allows
identifying robust biomarkers for susceptibility to develop T2D,
up to 9 years before the disease is diagnosed. Future studies
should aim at evaluating the potential role of these sphingolipids
on insulin secretion and insulin action and whether they can be
combined with other biochemical or genetic biomarkers to
improve their prediction power.
EXPERIMENTAL PROCEDURES
Animal Housing and Diet
Male mice from six different strains (C57BL/6J, DBA/2J, AJ, Balb/cJ, AKR/J,
and 129S2/SvPas) were housed on a 12-hr light/dark cycle and were fed a
standard rodent chow (SAFE A04) or HFHS diet (SAFE 235F, with 46% fat
and 38.5% carbohydrates expressed in Kcal/kg), ad libitum for 2, 10, 30,
and 90 days. At each time point, mice were phenotyped for body weight,
pancreas weight, fasting glycemia and insulinemia, glucose and insulinCell Reports 18, 2269–2279, February 28, 2017 2275
Figure 5. High Plasma Levels of Dihydroceramides May Be Associated with an Increased Risk of Future Diabetes
Decision curves, based on predicted probabilities from logistic regression tests. Standard net benefit is plotted against probability thresholds. Each plot
compares three models: model with Cer(d18:0), model with a clinical variable, model with both. All models are adjusted for age and sex. Higher net benefit over a
range of probability thresholds means that the model performs better as a predictor of T2D (as long as a threshold in that range is used for classifying individuals
as susceptible).tolerance, as well as glucose-stimulated insulin secretion assessed using pu-
rified islets. Mice were fasted for 5 hr before the different tests were performed.
The details of this study will be reported separately. The experimental protocol
was approved by the institutional animal care and use committee of the Paris
Diderot University (CEEA40, reference CERFE 2009-033).
Study Populations
Samples from the DESIR Cohort
The DESIR study (Balkau et al., 2008) was a population-based longitudinal
study on male and female volunteers between 30 and 65 years of age, con-
ducted in ten health examination centers in western France between 1994
and 2004. Study participants visited a center four times between 1994 and
2004, with an interval of approximately 3 years between visits. The time points
of the four visits are labeled year 0 (Y0), year 3 (Y3), year 6 (Y6), and year 9 (Y9).
The visits took place in the following time intervals: Y0: 07/1994–02/1996; Y3:
09/1997–11/1998; Y6: 10/2000–11/2001; Y9: 10/2003–10/2004. The study
was approved by the ethics committee (CCPPRB) of the Bice^tre Hospital first
in 1994 and then for addenda in 1997 and 2000. It was also approved by the
National Commission for Data Treatment (CNIL) in 1994, 1997, and 2008. All
subjects provided informed written consent.
For this work, three groups of diabetes cases were selected from the
study participants: all subjects who were determined to be diabetic for
the first time at Y3 (group 1), or at Y6 (group 2), or at Y9 (group 3), respec-
tively. Blood plasma samples for lipidomics analysis were picked from all
available time points before subjects were diabetic, and from the time point
when they were classified as diabetic for the first time, i.e., for group 1: Y0
and Y3; for group 2: Y0, Y3, and Y6; for group 3: Y0, Y3, Y6, and Y9. Sub-2276 Cell Reports 18, 2269–2279, February 28, 2017jects who were already diabetic at Y0 (baseline) were not included. In
addition, a group of control subjects was selected at random from the
entire pool of DESIR participants, and samples from all four time points
(Y0, Y3, Y6, and Y9) were picked. Due to the random selection without prior
filtering of subjects, the control group initially contained a small number of
participants with diabetes. Subjects with diabetes at any time point were
removed from the control group. Baseline clinical characteristics and details
of the numbers of samples analyzed in each of the groups are shown in
Tables S3 and S4.
Samples from the CoLaus Cohort
From the CoLaus (Cohorte Lausannoise) study (Firmann et al., 2008), a popu-
lation-based study of men and women living in Lausanne, Switzerland, plasma
samples for lipidomics analysis were obtained from two time points, year 0 (Y0)
and year 5 (Y5). A group of incident diabetes cases was picked, consisting of
participants who were diabetic at year 5 but not yet at year 0 and in the same
age range as the DESIR subjects. A group of sex- and age-matched control
subjects was also selected. Baseline clinical characteristics and details of
the numbers of samples analyzed in each of the groups are shown in Tables
S5 and S6. The institutional Ethics Committee of the University of Lausanne,
which afterward became the Ethics Commission of Canton Vaud, approved
the CoLaus baseline study in 2003 (reference 16/03) and renewed the approval
for two follow-ups in 2009 and 2014 (references 33/09 and 26/14). All partici-
pants gave their signed informed consent.
Definition of Diabetes Cases
In both cohorts, subjects were identified as incident diabetic cases either when
their fasting glucose level exceeded 7 mmol/L or when they were under treat-
ment for diabetes at the time of the health center visit.
Lipidomics Analysis
Lipid extraction, mass spectrometry (MS)-based lipid detection and data
processing for mouse and human samples was performed by Zora Biosci-
ences Oy (Jung et al., 2011). See Supplemental Experimental Procedures,
Lipid sample preparation and extraction and Mass spectrometric analyses
and data processing.
Data Preprocessing
Lipid concentrations that could not be measured and were missing from the
original lipidomics data files were imputed (see Supplemental Experimental
Procedures, Imputation of missing lipidomics values). In the DESIR cohort, a
batch effect in the lipidomics data, which resulted from processing the lipid
samples in two batches several months apart, was corrected using the
ComBat method (see Supplemental Experimental Procedures, Removing un-
wanted variation due to batch effect, DESIR cohort). Clinical data were log2-
transformed (except age and categorical or binary variables). Prior to the
log2 transformation, waist circumference in females was adjusted to account
for the difference in waist size between males and females (see Supplemental
Experimental Procedures, Data preprocessing in clinical variable’’).
Statistical Tests, DESIR Cohort
The main focus of this work was to compare the concentrations of ceramides
and related lipids in diabetes cases, before and after diabetes onset, to those
in the control group. Each group of cases from a certain time point (sample
collection period) was compared to the control samples from the same time
point. Time points were not mixed and not compared directly to one another
in order to avoid confounding with effects linked to sample storage duration
or collection date. This gave the following comparisons:
Year 0: Collection Dates 1994–1996, None of the Included Cases
Were Diabetic
d Group 1 (3 years before T2D) versus controls (not diabetic)
d Group 2 (6 years before T2D) versus controls (not diabetic)
d Group 3 (9 years before T2D) versus controls (not diabetic)
Year 3: Collection Dates 1997–1998, Group 1 Was Diabetic at This
Time Point
d Group 1 (diabetic) versus controls (not diabetic)
d Group 2 (3 years before T2D) versus controls (not diabetic)
d Group 3 (6 years before T2D) versus controls (not diabetic)
Year 6: Collection Dates 2000–2001, Group 2 Was Diabetic at This
Time Point
d Group 2 (diabetic) versus controls (not diabetic)
d Group 3 (3 years before T2D) versus controls (not diabetic)
Year 9: Collection Dates 2003–2004, Group 3 Was Diabetic at This
Time Point
d Group 3 (diabetic) versus controls (not diabetic)
The R language, version 3.2.1 was used. A linear model (R function lm) was
used for the comparisons, with variables for age and sex to address con-
founding factors. The statistical test was performed for each of the 37 lipid
species included in the lipidomics study, as well as the total concentrations
for each lipid class. Additional tests were run that included one more variable
in addition to age and sex, such as BMI, glycemia, or LDL. Within each
group/time point, the p values from all 37 lipid species were adjusted using
the Benjamini-Hochberg method to correct for multiple testing. In addition,
interquartile-range odds ratios were computed using logistic regression
models with different covariates. These are the odds ratios per increase in
lipid concentration by an amount equal to the interquartile range, i.e., the
magnitude of the interval between the top and the bottom quartile. The
lrm() function in the R package rms (Harrel, 2016), version 4.4-2, was used
with default parameters.
Statistical Tests, COLAUS Cohort
For the CoLaus cohort, the statistical tests with linear models were performed
in the same way as for the DESIR cohort. Cases were compared to controls at
year 0 and, in a separate test, at year 5. Interquartile odds ratios for year 0 were
also computed with the same method as described above for the DESIR
cohort.Decision Curve Analysis
Logistic regression models were used to obtain predicted probabilities (of be-
ing a future diabetic) for all individuals. This was done separately for each
participant group at each time point with control samples from the same
time point. A 10-fold cross-validation scheme was applied: data within each
group (consisting of cases and controls) was divided into ten equal-sized
parts. Nine parts were used to calculate regression coefficients, and then
probabilities were computed for the tenth part. This was repeated until each
data part had been left out once, and all individuals had a predicted probability
assigned to them. All logistic regression models included age and sex as po-
tential confounders, and a clinical variable or the Cer(d18:0) concentration or
both clinical variable and Cer(d18:0) as the predictors of interest.
Decision curve analysis based on net benefits (Rousson and Zumbrunn,
2011; Vickers and Elkin, 2006) was performed to quantify the predictive value
of the plasma concentration of lipid class Cer(d18:0). Decision curve analysis is
commonly used on predicted probabilities resulting from logistic regression
tests. Similar to an ROC analysis, it assumes that participants will be classified
into ‘‘positives’’ and ‘‘negatives’’ by applying a threshold to the predicted prob-
abilities. It allows to compute a ‘‘net benefit’’ of using a particular statistical
model for prediction, across all possible probability thresholds.
The same predictor variables (measures known or thought to be associated
with diabetes) were used in this analysis as for the computation of odds ratios:
BMI, LDL, glucose, insulin, HOMA2-%B, HOMA2-%s, waist circumference,
and bioimpedance. For each of these variables, a logistic regression model
was defined that also included age and sex as covariates, and the same
was done for the lipid class Cer(d18:0). A decision curve plot was prepared
for each clinical variable to visually compare the performances of (1) the model
with the lipid, (2) themodel with the clinical variable, and (3) an additionalmodel
with both clinical variable and lipid. Our principal interest was to see if
combining the clinical variable and the lipid in a model improved prediction
over the model with only the clinical variable. We looked at the range of risk
thresholds between 0.6 and 0.8 to compare the performance of predictive
models. The net benefit was not adjusted for population prevalence of dia-
betes, so the risk thresholds on the x axis of the plots reflect the risk within
the case-control study setting, where about half of all participants are cases
(i.e., not the risk of an individual picked at random from the population). This
does not matter for comparing decision curves with one another.
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